{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:13Z","timestamp":1791414133330,"version":"4.3.3"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The inhaled form of\n            <jats:italic>Bacillus anthracis<\/jats:italic>\n            infection may be fatal to humans. The current standard of care for inhalational anthrax postexposure prophylaxis is ciprofloxacin therapy twice daily for 60 days. The potent in vitro activity of oritavancin, a semisynthetic lipoglycopeptide, against\n            <jats:italic>B<\/jats:italic>\n            .\n            <jats:italic>anthracis<\/jats:italic>\n            (MIC against Ames strain, 0.015 \u03bcg\/ml) prompted us to test its efficacy in a mouse aerosol-anthrax model. In postexposure prophylaxis dose-ranging studies, a single intravenous (i.v.) dose of oritavancin of 5, 15, or 50 mg\/kg 24 h after a challenge with 50 to 75 times the median lethal dose of Ames strain spores provided 40, 70, and 100% proportional survival, respectively, at 30 days postchallenge. Untreated animals died within 4 days of challenge, whereas 90% of control animals receiving ciprofloxacin at 30 mg\/kg intraperitoneally twice daily for 14 days starting 24 h after challenge survived. Oritavancin demonstrated significant activity post symptom development; a single i.v. dose of 50 mg\/kg administered 42 h after challenge provided 56% proportional survival at 30 days. In a preexposure prophylaxis study, a single i.v. oritavancin dose of 50 mg\/kg administered 1, 7, 14, or 28 days before lethal challenge protected 90, 100, 100, and 20% of mice at 30 days; mice treated with ciprofloxacin 24 h or 24 and 12 h before challenge all died within 5 days. Efficacy in pre- and postexposure models of inhalation anthrax, together with a demonstrated low propensity to engender resistance, promotes further study of oritavancin pharmacokinetics and efficacy in nonhuman primate models.\n          <\/jats:p>","DOI":"10.1128\/aac.00360-08","type":"journal-article","created":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T00:44:26Z","timestamp":1215477866000},"page":"3350-3357","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of Oritavancin in a Murine Model of\n            <i>Bacillus anthracis<\/i>\n            Spore Inhalation Anthrax"],"prefix":"10.1128","volume":"52","author":[{"given":"H. S.","family":"Heine","sequence":"first","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bassett","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Miller","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bassett","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. E.","family":"Ivins","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lehoux","sequence":"additional","affiliation":[{"name":"Targanta Therapeutics, St-Laurent, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. F.","family":"Arhin","sequence":"additional","affiliation":[{"name":"Targanta Therapeutics, St-Laurent, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"T. R.","family":"Parr","sequence":"additional","affiliation":[{"name":"Targanta Therapeutics, St-Laurent, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Moeck","sequence":"additional","affiliation":[{"name":"Targanta Therapeutics, St-Laurent, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2003.tb00628.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01513-07"},{"key":"e_1_3_2_4_2","first-page":"85","year":"2007","unstructured":"Arhin, F. F., I. Sarmiento, T. R. Parr, Jr., and G. Moeck. 2007. Mechanisms of action of oritavancin in Staphylococcus aureus, abstr. C1-1471, p. 85. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"Mechanisms of action of oritavancin in Staphylococcus aureus, abstr. C1-1471"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.841-851.2006"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1700-1706.2003"},{"key":"e_1_3_2_7_2","first-page":"306","volume":"340","year":"1992","unstructured":"Bradaric, N., and V. Punda-Polic. 1992. Cutaneous anthrax due to penicillin-resistant Bacillus anthracis transmitted by an insect bite. Lancet340:306-307.","journal-title":"Lancet"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00464-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4873-4877.2004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1766-1766.2000"},{"key":"e_1_3_2_11_2","unstructured":"Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. 2008"},{"key":"e_1_3_2_12_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014seventh edition. 2006"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5099-5106.2005"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365549109024319"},{"key":"e_1_3_2_15_2","first-page":"37988","volume":"67","year":"2002","unstructured":"Federal Register. 2002. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed. Regist.67:37988-37998.","journal-title":"Final rule. Fed. Regist."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.148-152.2005"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1239"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1955.00250140109012"},{"key":"e_1_3_2_19_2","first-page":"34","year":"2007","unstructured":"Heine, H. S., C. M. Rubino, J. Bassett, L. Miller, P. G. Ambrose, S. M. Bhavnani, A. Forrest, G. L. Drusano, A. Beaudry, J. Li, N. Janjic, and S. C. Gill. 2007. Pharmacokinetic-pharmacodynamic (PK-PD) assessment of faropenem (FAR) in a lethal murine-Bacillus anthracis (BA) inhalation post-exposure prophylaxis model, abstr. A-1435, p. 34. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"Pharmacokinetic-pharmacodynamic (PK-PD) assessment of faropenem (FAR) in a lethal murine-Bacillus anthracis (BA) inhalation post-exposure prophylaxis model, abstr. A-1435"},{"key":"e_1_3_2_20_2","first-page":"232","year":"2005","unstructured":"Heine, H. S., J. Bassett, and L. Miller. 2005. In vitro and in vivo activity of dalbavancin (DAL) against Bacillus anthracis (BA), abstr. F-2079, p. 232. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"In vitro and in vivo activity of dalbavancin (DAL) against Bacillus anthracis (BA), abstr. F-2079"},{"key":"e_1_3_2_21_2","first-page":"23","year":"2007","unstructured":"Heine, H. S., J. Bassett, L. Miller, A. Basset, T. R. Parr, Jr., and G. Moeck. 2007. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax, abstr. A-101, p. 23. Abstr. 107th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.","journal-title":"Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax, abstr. A-101"},{"key":"e_1_3_2_22_2","first-page":"10","year":"2004","unstructured":"Heine, H. S., J. Bassett, L. Miller, G. P. Andrews, and W. R. Byrne. 2004. Efficacy of daptomycin against Bacillus anthracis (anthrax) in a murine model of anthrax-spore inhalation, abstr. A-051, p. 10-11. Abstr. 104th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.","journal-title":"Efficacy of daptomycin against Bacillus anthracis (anthrax) in a murine model of anthrax-spore inhalation, abstr. A-051"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-06"},{"key":"e_1_3_2_24_2","first-page":"173","year":"2001","unstructured":"Heine, H. S., R. Dicks, and G. Andrews. 2001. In vitro activity of oritavancin (LY333328), levofloxacin, meropenem, GAR936 and linezolid against strains of Bacillus anthracis, abstr. E-524, p. 173. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"In vitro activity of oritavancin (LY333328), levofloxacin, meropenem, GAR936 and linezolid against strains of Bacillus anthracis, abstr. E-524"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2236"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.182.10.2928-2936.2000"},{"key":"e_1_3_2_27_2","first-page":"77","year":"2006","unstructured":"Leffel, E. K., and L. M. Pitt. 2006. Anthrax, p. 77-93. In J. R. Swearengen (ed.), Biodefense. Research methodology and animal models. CRC Press Taylor and Francis, Boca Raton, FL.","journal-title":"Biodefense"},{"key":"e_1_3_2_28_2","first-page":"38","year":"2006","unstructured":"Lehoux, D., F. F. Arhin, I. Fadhil, K. Laquerre, V. Ostiguy, I. Sarmiento, G. Moeck, and T. R. Parr, Jr. 2006. Oritavancin demonstrates rapid and sustained bactericidal activity in the rat granuloma pouch model of Staphylococcus aureus infection, abstr. B-404, p. 38. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"Oritavancin demonstrates rapid and sustained bactericidal activity in the rat granuloma pouch model of Staphylococcus aureus infection, abstr. B-404"},{"key":"e_1_3_2_29_2","unstructured":"Efficacy of oritavancin in a mouse model of Streptococcus pneumoniae pneumonia abstr. P-1781 2007"},{"key":"e_1_3_2_30_2","first-page":"187","volume":"212","year":"1993","unstructured":"Leitenberg, M. 1993. The biological weapons program of the former Soviet Union. Biologicals212:187-191.","journal-title":"Biologicals"},{"key":"e_1_3_2_31_2","first-page":"95","volume":"68","year":"1990","unstructured":"Lightfoot, N. F., R. J. D. Scott, and P. C. B. Turnbull. 1990. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med. Bull.68(Suppl.):95-98.","journal-title":"Salisbury Med. Bull."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01875-06"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.2040-2042.2003"},{"key":"e_1_3_2_34_2","first-page":"76","year":"2006","unstructured":"McKay, G. A., I. Fadhil, S. Beaulieu, S. Ciblat, A. Rafai Far, G. Moeck, and T. R. Parr, Jr. 2006. Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin-resistant enterococci, abstr. C1-682, p. 76. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin-resistant enterococci, abstr. C1-682"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1086\/421491","volume":"39","year":"2004","unstructured":"Meyerhoff, A., R. Albrecht, J. M. Meyer, P. Dionne, K. Higgins, and D. Murphy. 2004. US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. Clin. Infect. Dis.39:303-308.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_36_2","first-page":"34","year":"2007","unstructured":"Nguyen, H. A., O. Denis, A. Vergison, P. M. Tulkens, M. Struelens, and F. Van Bambeke. 2007. Comparative intracellular activity of 10 antistaphylococcal antibiotics (AABS) against a stable small colony variant (SCV) of S. aureus in a model of human THP-1 macrophages, abstr. A-1437, p. 34. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"Comparative intracellular activity of 10 antistaphylococcal antibiotics (AABS) against a stable small colony variant (SCV) of S. aureus in a model of human THP-1 macrophages, abstr. A-1437"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.5.429"},{"key":"e_1_3_2_38_2","first-page":"739","volume":"31","year":"1950","unstructured":"Pollock, M. R. 1950. Penicillinase adaptation in B. cereus: adaptive enzyme formation in the absence of free substrate. Br. J. Exp. Pathol.31:739-753.","journal-title":"Br. J. Exp. Pathol."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.2.225"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2362-2365.2003"},{"key":"e_1_3_2_41_2","first-page":"64","year":"2007","unstructured":"Sivko, G., K. Gebhardt, P. Olson, R. Hunt, Z. Xu, P. Flavin, D. Eiznhamer, and M. Flavin. 2007. Efficacy of cethromycin against a lethal inhalation anthrax challenge in rhesus macaques, abstr. B-2031, p. 64-65. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"Efficacy of cethromycin against a lethal inhalation anthrax challenge in rhesus macaques, abstr. B-2031"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.2853-2860.2004"},{"key":"e_1_3_2_43_2","first-page":"86","year":"2007","unstructured":"Wang, T., S. Walker, and D. E. Kahne. 2007. Probing the mechanism of inhibition of bacterial peptidoglycan glycotransferases by glycopeptide analogs, abstr. C1-1474, p. 86. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.","journal-title":"Probing the mechanism of inhibition of bacterial peptidoglycan glycotransferases by glycopeptide analogs, abstr. C1-1474"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00360-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00360-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:43:04Z","timestamp":1645472584000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00360-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1128\/AAC.00360-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.00360-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"2008-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-06-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}